Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Takeda Chemical Ind., Ltd.

Takeda Chemical Corporation

Kitasato Kenkyushio

Nobuhiro Inatomi

Setsuo Harada

Seiichi Tanida

Yasunori Funabashi

Shigeharu Tanayama

Takashi Sohda

Jun Terauchi

Hidefumi Yukimasa

Masafumi Nakao

Satoru Oi

Hideaki Nagaya

Fumihiko Sato

The present invention provides a therapeutic agent and methods thereof for the treatment for irritable bowel syndrome. The agent comprises a compound represented by formula (I): wherein, Rrepresents an optionally substituted hydrocarbon group, etc., Rrepresents a hydrogen atom or an optionally substituted hydrocarbon group, Rrepresents a hydrogen atom, an optionally substituted hydrocarbon group, etc., X represents CHR, NR, CO, O or S (wherein, Rrepresents a hydrogen atom, an optionally substituted hydrocarbon group, etc.), Y represents C, CH or N, represents a single bond or double bond, ring A represents an optionally substituted 5- to 7-membered oxygen-containing heterocyclic ring, ring B represents an optionally substituted benzene ring, and m represents an integer of 1 to 4, or a salt thereof, wherein the compound represented by formula (I) or a salt thereof is (S)&#x2014;N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.

Therapeutic agent for irritable bowel syndrome and methods thereof

Disclosed are (1) a structurally novel 6,9-hemiacetal- erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions br a salt thereof, which has an excellent gastrointestinal function promoting effect and is low in toxicity; (2) a process for preparing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which comprises reacting a 6,9-hemiacetal-erythromycin derivative or a salt thereof with an organism-derived oxidase; and (3) a gastrointestinal function promoting agent containing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof.

15-hydroxy 6,9-hemiacetal erythromycin compounds

Phosphorylamides, their preparation and use

Disclosed are (1) a structurally novel 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which has an excellent gastrointestinal function promoting effect and is low in toxicity; (2) a process for preparing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which comprises reacting a 6,9-hemiacetal-erythromycin derivative or a salt thereof with an organism-derived oxidase; and (3) a gastrointestinal function promoting agent containing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof.

14 and/or 15-hydroxy 6,9 hemiacetal erythromycin derivatives

A compound of the formula ##STR1## wherein R.sup.1 stands for a substituent on benzene ring, R.sup.2 and R.sup.3 independently stand for hydrogen or methyl, and n denotes 0 or 1, or a pharmacologically acceptable salt thereof is useful for prophylaxis and treatment of peptic ulcers (e.g. gastric ulcer, duodenal ulcer) and gastritis.

Certain 2-[(4-difluoromethoxy-2-pyridyl)-methylthio or

Growing community of inventors

Osaka, Japan

Nobuhiro Inatomi